Cargando…

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

Immunologically-cold tumors including glioblastoma (GBM) are refractory to checkpoint blockade therapy, largely due to extensive infiltration of immunosuppressive macrophages (Mϕs). Consistent with a pro-tumor role of IL-6 in alternative Mϕs polarization, we here show that targeting IL-6 by genetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fan, He, Zhenqiang, Duan, Hao, Zhang, Duo, Li, Juehui, Yang, Huijuan, Dorsey, Jay F., Zou, Wei, Nabavizadeh, S. Ali, Bagley, Stephen J., Abdullah, Kalil, Brem, Steven, Zhang, Lin, Xu, Xiaowei, Byrne, Katelyn T., Vonderheide, Robert H., Gong, Yanqing, Fan, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187342/ https://www.ncbi.nlm.nih.gov/pubmed/34103524 http://dx.doi.org/10.1038/s41467-021-23832-3

Ejemplares similares

PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
por: Liu, Tianrun, et al.
Publicado: (2018)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

(18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling
por: Henderson, Fraser, et al.
Publicado: (2020)

Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
por: Wang, Qirui, et al.
Publicado: (2018)

Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
por: Mohan, Suyash, et al.
Publicado: (2021)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma
por: Fathi Kazerooni, Anahita, et al.
Publicado: (2022)

Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma
por: Nabavizadeh, S. Ali, et al.
Publicado: (2019)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging
por: Akbari, Hamed, et al.
Publicado: (2021)

Factors Associated with Increased Survival after Surgical Resection of Glioblastoma in Octogenarians
por: Abdullah, Kalil G., et al.
Publicado: (2015)

Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma
por: Nabavizadeh, Seyed Ali, et al.
Publicado: (2020)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma
por: Schwab, Robert D., et al.
Publicado: (2018)

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)

Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology
por: Yang, Jun, et al.
Publicado: (2020)

Biomimetic hypoxia-triggered RNAi nanomedicine for synergistically mediating chemo/radiotherapy of glioblastoma
por: Wang, Zhen, et al.
Publicado: (2023)

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
por: Carpenter, Erica L, et al.
Publicado: (2009)

TGFβ signaling-induced miRNA participates in autophagic regulation by targeting PRAS40 in mesenchymal subtype of glioblastoma
por: Xie, Yingbin, et al.
Publicado: (2020)

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
por: Choi, John, et al.
Publicado: (2021)

Resveratrol-Coated Gold Nanoflowers for CT Imaging and Apoptosis/Photothermal Synergistic Therapy of Malignant Melanoma
por: Yang, Tianye, et al.
Publicado: (2023)

OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy
por: Shibahara, Ichiyo, et al.
Publicado: (2015)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
por: Chen, Wei-jun, et al.
Publicado: (2020)

The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells
por: Atif, Fahim, et al.
Publicado: (2015)

Drug and disease signature integration identifies synergistic combinations in glioblastoma
por: Stathias, Vasileios, et al.
Publicado: (2018)

Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs
por: Zhai, Kevin, et al.
Publicado: (2021)

Siderol Inhibits Proliferation of Glioblastoma Cells and Acts Synergistically with Temozolomide
por: Giannakopoulou, Maria, et al.
Publicado: (2022)

TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells
por: Pinet, Sandra, et al.
Publicado: (2016)

GLIOMA-05 A NOVEL CONCEPT FOR TREATMENT OF GLIOBLASTOMA: VAGUS NERVE ELECTRICAL STIMULATION FOR SUPPRESSION OF CYTOKINE (IL-6) SIGNALING
por: Brem, Steven
Publicado: (2023)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Macrophage-targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis
por: Tian, Na, et al.
Publicado: (2023)

CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation
por: Mester, Tünde, et al.
Publicado: (2016)

Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer
por: Lin, Yilin, et al.
Publicado: (2023)

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
por: Medina-Echeverz, José, et al.
Publicado: (2019)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma
por: Chakwizira, Arthur, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oqjk7vpcsb15keopgjjljqi6i9